IBERE PHARMACEUTICALS Balance Sheet

Ask AI

Financial Statements

In millions of USD, except per-share amounts

	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021
ASSETS
Current assets
Cash
Prepaid expenses
Total Current Assets
Marketable securities held in trust account
TOTAL ASSETS
LIABILITIES, REDEEMABLE ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT
Current liabilities
Accrued expenses
Accrued offering costs
Promissory notes - related party
Total Current Liabilities
Deferred underwriting fee payable
Warrant liability
TOTAL LIABILITIES
Class A ordinary shares subject to possible redemption 13,800,000 shares at September 30, 2022 and December 31, 2021, at redemption value
Class A common stock subject to possible redemption
Total class A ordinary shares subject to possible redemption 13,800,000 shares at September 30, 2022 and December 31, 2021, at redemption value
Shareholders' Deficit
Ordinary shares
Class A ordinary shares
Class B ordinary shares
Additional paid-in capital
Accumulated deficit
Total Shareholders' Deficit
TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT

Comments